Caution should be exercised when assessing ivermectin for the treatment of COVID-19 in systematic reviews

Rev Med Virol. 2022 Sep;32(5):e2317. doi: 10.1002/rmv.2317. Epub 2021 Dec 9.

Authors

Jiawen Deng¹, Fangwen Zhou¹, Kiyan Heybati², Kyra Kavanagh³

Affiliations

¹ Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
² Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
³ Faculty of Science, Carleton University, Ottawa, Ontario, Canada.

PMID: 34888992
DOI: 10.1002/rmv.2317

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Humans
Ivermectin / adverse effects
SARS-CoV-2
Systematic Reviews as Topic

Substances

Antiviral Agents
Ivermectin